1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Epizyme CEO Bazemore: Cancer Survivor Brings Patient Perspective

 
• By Mandy Jackson

Epizyme Inc. president and CEO Robert Bazemore's first thought when he was diagnosed with Stage 4 diffuse large B-cell lymphoma (DLBCL) – an advanced form of non-Hodgkin lymphoma (NHL) with a 50-50 chance of survival – was that his young children wouldn't remember him when he was gone.

Epizyme Inc. president and CEO Robert Bazemore's first thought when he was diagnosed with Stage 4 diffuse large B-cell lymphoma (DLBCL) – an advanced form of non-Hodgkin lymphoma (NHL) with a 50-50 chance of survival – was that his young children wouldn't remember him when he was gone.

Twelve years later at Epizyme, where the lymphoma survivor took over the CEO role from Robert Gould in September, Bazemore...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By Manas Mishra

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

What Incyte Investors Expect From New CEO Bill Meury

 
• By Andrew McConaghie

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Nektar Bounces Back As Eczema Drug Rezpeg Heads For Phase III

 
• By Kevin Grogan

Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.

More from Therapy Areas

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By Lisa Takagi

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 
• By Alaric DeArment

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.